Forma Therapeutics, Inc., a Watertown, Mass. – based clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, closed a $100m Series D financing.
The round was led by RA Capital Management, with participation from Cormorant Asset Management, Wellington Management, Samsara BioCapital and funds managed by Janus Henderson Investors, as well as an undisclosed healthcare investment fund.
The company intends to use the funds to continue to advance FT-4202, its pyruvate kinase-R (PKR) activator in clinical development as a potential disease-modifying therapy for sickle cell disease (SCD). A Phase 1/2 study is currently enrolling patients with sickle cell disease.
The funding will also support Forma’s deep pipeline, including FT-7051, a novel and potent selective inhibitor of CBP/p300 binding to DNA for androgen receptor-driven cancers, which is also being investigated for its potential in AR-v7 mCRPC; olutasidenib, a next generation inhibitor of mutated isocitrate dehydrogenase 1 (IDH1m) in development to treat gliomas, relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS) and other IDH1m solid tumors; and progress on a variety of preclinical programs.
Led by Frank Lee, chief executive officer, Forma Therapeutics focuses on the discovery, development and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. A fully-integrated biopharmaceutical company, its validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates